JP2010503854A - 分析物濃度を求める方法 - Google Patents
分析物濃度を求める方法 Download PDFInfo
- Publication number
- JP2010503854A JP2010503854A JP2009528199A JP2009528199A JP2010503854A JP 2010503854 A JP2010503854 A JP 2010503854A JP 2009528199 A JP2009528199 A JP 2009528199A JP 2009528199 A JP2009528199 A JP 2009528199A JP 2010503854 A JP2010503854 A JP 2010503854A
- Authority
- JP
- Japan
- Prior art keywords
- analyte
- sample
- complex
- binding
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012491 analyte Substances 0.000 title claims abstract description 135
- 238000000034 method Methods 0.000 title claims abstract description 47
- 230000027455 binding Effects 0.000 claims abstract description 54
- 239000012530 fluid Substances 0.000 claims abstract description 31
- 239000000126 substance Substances 0.000 claims abstract description 22
- 238000001514 detection method Methods 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 13
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims description 13
- 230000003472 neutralizing effect Effects 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 238000011898 label-free detection Methods 0.000 claims 1
- 239000000523 sample Substances 0.000 description 90
- 239000000243 solution Substances 0.000 description 20
- 238000002156 mixing Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000000872 buffer Substances 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 238000003556 assay Methods 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000012488 sample solution Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 6
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 6
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000004611 spectroscopical analysis Methods 0.000 description 5
- 239000002699 waste material Substances 0.000 description 5
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 description 4
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 238000005401 electroluminescence Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102100024078 Plasma serine protease inhibitor Human genes 0.000 description 2
- 108010001953 Protein C Inhibitor Proteins 0.000 description 2
- 229940122929 Protein C inhibitor Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000003380 quartz crystal microbalance Methods 0.000 description 2
- 238000001028 reflection method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010897 surface acoustic wave method Methods 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150111781 PGL1 gene Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012327 Ruthenium complex Substances 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000001210 attenuated total reflectance infrared spectroscopy Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 238000012923 label-free technique Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1484—Optical investigation techniques, e.g. flow cytometry microstructural devices
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Abstract
【選択図】 なし
Description
a)実質的にあらゆる分析物複合体を解離し実質的に全ての分析物を遊離形態で提供するのに充分な程度に分析物と分析物結合性物質との間の結合親和性を低下させる条件に試料を付す。
b)分析物と分析物結合性物質との間の結合親和性を回復させる条件に試料を付す。
c)結合親和性が回復した直後、分析物の実質的な複合体再形成が起こる前に、試料中の遊離分析物の濃度を決定する。
a)上記態様の方法に従って試料中の分析物の総濃度を決定する。
b)試料中の遊離分析物の濃度を決定する。
ここで、工程a)とb)で得られた濃度の差が複合体結合分析物の濃度を表す。
a)実質的にあらゆる分析物複合体を解離し実質的に全ての分析物を遊離形態で提供するのに充分な程度に分析物と分析物結合性物質との間の結合親和性を低下させる条件に試料を付す。
b)分析物と分析物結合性物質との間の結合親和性を回復させる条件に試料を付す。
c)結合親和性が回復した直後、分析物の実質的な複合体再形成が起こる前に、分析物が固定化されている固体支持体と試料を接触させる。
d)固定化された分析物に結合した物質を分析する。
Biacore(登録商標)T100(Biacore AB(スウェーデン、ウプサラ))を使用した。この機器は、センサーチップ上の金表面における表面プラズモン共鳴(SPR)検出に基づいており、4つの個別に検出されるフローセル(Fc1〜Fc4、個別又は直列)に試料を通し緩衝液を流すためにマイクロ流体システム(一体型マイクロ流体カートリッジ(IFC))を使用する。IFCはドッキング機構によりBiacore(登録商標)T100機器内に押し込まれてセンサーチップと接触する。
ヒト血清アルブミン(Sigma−Aldrich、Missouri、USA)を10mMアセテート(pH5.0)中で50μg/mlに希釈し、標準アミンカップリング(アミンカップリングキット、Biacore AB)を用いてBiacore(登録商標)T100内のフローセル3(Fc3)に約9kRUで固定化した。
標準アミンカップリング(アミンカップリングキット、Biacore AB)を用いて、10mMアセテート(pH4.5、Biacore AB)中の20μg/mlのβ−2−マイクログロブリン(β2μ)(社内試薬)をBiacore(登録商標)T100内のフローセル3(Fc3)に約1.7kRUで固定化した。
標準アミンカップリング(アミンカップリングキット、Biacore AB)を用いて、10mMアセテート(pH4.5、Biacore AB)中の20μg/mlのβ2μ(社内試薬)をBiacore(登録商標)T100内のフローセル3(Fc3)に約1.7kRUで固定化した。
Claims (16)
- 分析物の少なくとも一部が分析物結合性物質との複合体として存在する流体試料中の分析物の総濃度を決定する方法であって、
a)試料を、実質的にあらゆる分析物複合体を解離すると共に実質的に全ての分析物を遊離形態で提供するように分析物と分析物結合性物質との間の結合親和性を充分に低下させる条件に付す工程、
b)試料を、分析物と分析物結合性物質との間の結合親和性を回復させる条件に付す工程、及び
c)結合親和性が回復した直後、分析物の実質的な複合体再形成が起こる前に、試料中の遊離分析物の濃度を決定する工程
を含んでなる方法。 - 試料中の遊離分析物の決定が、分析物結合性リガンドが固定化されている固体支持体と試料を接触させて、固定化されたリガンドに分析物を結合させることを含む、請求項1記載の方法。
- 工程a)において結合親和性を低下させ、工程b)において結合親和性を回復させる条件が、試料のpH−値を変化させることからなる、請求項1又は請求項2記載の方法。
- 複合体が酸で解離可能な複合体であり、工程a)が試料を酸性化することを含み、工程b)が酸性化された試料を中和することを含む、請求項1乃至請求項3のいずれか1項記載の方法。
- 複合体が免疫複合体である、請求項1乃至請求項4のいずれか1項記載の方法。
- 分析物が治療用抗体に対する抗体であり、試料が治療用抗体を含有する、請求項1乃至請求項5のいずれか1項記載の方法。
- 請求項1の工程c)において、分析物の濃度を、標識を用いない検出技術を用いて決定する、請求項1乃至請求項6のいずれか1項記載の方法。
- 標識を用いない検出技術が、エバネッセント波感知、特に表面プラズモン共鳴(SPR)を含む、請求項7記載の方法。
- 少なくとも工程c)をフローセル内で行う、請求項1乃至請求項8のいずれか1項記載の方法。
- フローセルが、固定化されたリガンドを有する検出領域、及び接合部を介して第1及び第2の導管に接続された入口を含んでおり、請求項1の工程b)が解離された分析物複合体を有する試料を第1の導管に、また分析物の結合能を回復させることができる流体を第2の導管に流すことを含んでいて、その結果2つの流体がフローセルの入口導管の接合部で混合し、この混合した流体がフローセルの検出領域上を通過する、請求項9記載の方法。
- (i)検出領域と接合部との間隔、及び(ii)第1及び第2の導管内の流体の流速を、混合した流体が検出領域に到達したときに、分析物の結合能が実質的に回復しているが、分析物の複合体再形成が実質的に起こっていないように選択する、請求項10記載の方法。
- 第1の導管内を流れる流体が酸性化された試料であり、第2の導管内を流れる流体がアルカリ性流体である、請求項10又は請求項11記載の方法。
- 混合した流体が検出領域に到達したとき、酸性化された試料が実質的に中和されているが、分析物の複合体再形成は実質的に起こらない、請求項11又は請求項12記載の方法。
- 試料中の複合体結合分析物の濃度を決定する方法であって、
a)請求項1乃至請求項13のいずれか1項記載の方法に従って試料中の分析物の総濃度を決定する工程、
b)試料中の遊離分析物の濃度を決定する工程
を含んでなり、工程a)及びb)で得られた濃度の差が複合体結合分析物の濃度を表す、方法。 - 工程a)における総分析物及び工程b)における遊離分析物の決定が、分析物結合性リガンドが固定化されている固体支持体と試料を接触させて、固定化されたリガンドに分析物を結合させることを含む、請求項14記載の方法。
- 分析物を含有する試料中でその分析物が1種以上の物質と複合体を形成する能力を決定する方法であって、
a)試料を、実質的にあらゆる分析物複合体を解離すると共に実質的に全ての分析物を遊離形態で提供するように分析物と分析物結合性物質との間の結合親和性を充分に低下させる条件に付す工程、
b)試料を、分析物と分析物結合性物質との間の結合親和性を回復させる条件に付す工程、
c)結合親和性が回復された直後、分析物の実質的な複合体再形成が起こる前に、分析物が固定化されている固体支持体と試料を接触させる工程、及び
d)固定化された分析物に結合した物質を分析する工程
を含んでなる方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82566406P | 2006-09-14 | 2006-09-14 | |
SE0601891 | 2006-09-14 | ||
PCT/SE2007/000792 WO2008033073A1 (en) | 2006-09-14 | 2007-09-12 | A method of determining analyte concentration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010503854A true JP2010503854A (ja) | 2010-02-04 |
JP2010503854A5 JP2010503854A5 (ja) | 2010-10-14 |
Family
ID=39184031
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009528199A Pending JP2010503854A (ja) | 2006-09-14 | 2007-09-12 | 分析物濃度を求める方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US8263415B2 (ja) |
EP (1) | EP2062052A4 (ja) |
JP (1) | JP2010503854A (ja) |
WO (1) | WO2008033073A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012161287A1 (ja) * | 2011-05-24 | 2012-11-29 | コニカミノルタアドバンストレイヤー株式会社 | 薄膜状素材の熱応答性測定方法および薄膜膜厚測定装置 |
JP2013515260A (ja) * | 2009-12-22 | 2013-05-02 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 混合の改善された分析方法 |
JP2015531487A (ja) * | 2012-10-03 | 2015-11-02 | ユィロス・パテント・アクチボラグGyros Patent AB | 酸性条件でアナライトを測定するための方法およびキット |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110201022A1 (en) * | 2008-07-30 | 2011-08-18 | Biomarin Pharmaceutical Inc. | Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase |
JP2010071693A (ja) * | 2008-09-16 | 2010-04-02 | Fujifilm Corp | センシング方法、センシング装置、検査チップおよび検査キット |
DE102008062620B4 (de) * | 2008-12-10 | 2012-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Vorrichtung und Verfahren zur Detektion von in flüssigen Proben enthaltenen Analytmolekülen |
WO2010107385A1 (en) * | 2009-03-20 | 2010-09-23 | Ge Healthcare Bio-Sciences Ab | Method for detection of an enzyme-substrate reaction |
EP2553457B1 (en) | 2010-03-30 | 2018-07-11 | GE Healthcare Bio-Sciences AB | Method for determination of binding stoichiometry |
US8546149B2 (en) | 2010-08-27 | 2013-10-01 | Intervet Inc. | Potency test for vaccine formulations |
US20160223536A1 (en) * | 2013-10-10 | 2016-08-04 | Song Diagnostic Research Llc | Improved Lateral Flow Assays |
ES2772751T3 (es) | 2017-03-07 | 2020-07-08 | Hoffmann La Roche | Procedimiento para determinar una concentración de analito |
IL277890B2 (en) * | 2018-04-11 | 2024-03-01 | Regeneron Pharma | Methods for quantification of IL-33 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07140144A (ja) * | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的IgE抗体の測定方法および抗原抗体複合体の測定方法 |
JP2005040784A (ja) * | 2003-07-10 | 2005-02-17 | Citizen Watch Co Ltd | マイクロ化学チップ温度調節装置 |
JP2006078364A (ja) * | 2004-09-10 | 2006-03-23 | Ntt Advanced Technology Corp | 表面プラズモン測定装置および測定方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4292296A (en) * | 1978-09-12 | 1981-09-29 | Baxter Travenol Laboratories, Inc. | Diagnostic method |
US4459359A (en) * | 1981-11-19 | 1984-07-10 | New York Blood Center, Inc. | Sensitive immunoassays of antigens or antibodies sequestered within immune complexes |
US5219730A (en) * | 1982-09-28 | 1993-06-15 | New York University | Idiotype-anti-idiotype immunoassay |
US4703001A (en) * | 1985-10-23 | 1987-10-27 | Synbiotics, Corporation | Immunoassay for the detection of serum analytes using pH dependent chastropic acids |
SE8804074D0 (sv) * | 1988-11-10 | 1988-11-10 | Pharmacia Ab | Sensorenhet och dess anvaendning i biosensorsystem |
SE462454B (sv) * | 1988-11-10 | 1990-06-25 | Pharmacia Ab | Maetyta foer anvaendning i biosensorer |
SE462408B (sv) * | 1988-11-10 | 1990-06-18 | Pharmacia Ab | Optiskt biosensorsystem utnyttjande ytplasmonresonans foer detektering av en specific biomolekyl, saett att kalibrera sensoranordningen samt saett att korrigera foer baslinjedrift i systemet |
US5063165A (en) * | 1988-12-22 | 1991-11-05 | Syntex (U.S.A.) Inc. | Geminal diphenyl derivatives and their use in immunoassays |
EP0440044A1 (en) | 1990-01-31 | 1991-08-07 | Abbott Laboratories | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing |
US5256541A (en) * | 1991-11-06 | 1993-10-26 | Sangstat Medical Corporation | Detection of soluble alloantigen immune complexes |
IT1254858B (it) * | 1992-04-14 | 1995-10-11 | Metodo per la determinazione della frazione libera di sostanze presenti nei fluidi biologici. | |
US5484706A (en) * | 1993-05-19 | 1996-01-16 | Pasteur Sanofi Diagnostics | Immunoassay for analytes in samples using alkylating agents |
US5593842A (en) * | 1994-09-20 | 1997-01-14 | Gideon Goldstein | Method of measuring thymopoietin proteins in plasma and serum including acidification of the plasma and serum |
US6200814B1 (en) * | 1998-01-20 | 2001-03-13 | Biacore Ab | Method and device for laminar flow on a sensing surface |
US20030003503A1 (en) * | 2001-06-29 | 2003-01-02 | Tsai Tenlin S. | Enhancing sensitivity and equimolar detection through modifications of the reaction environment |
GB2426050A (en) * | 2005-05-09 | 2006-11-15 | Orion Diagnostica Oy | Method of measuring binding rate using sonication |
-
2007
- 2007-09-12 EP EP07808806A patent/EP2062052A4/en not_active Withdrawn
- 2007-09-12 JP JP2009528199A patent/JP2010503854A/ja active Pending
- 2007-09-12 US US12/377,021 patent/US8263415B2/en active Active
- 2007-09-12 WO PCT/SE2007/000792 patent/WO2008033073A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07140144A (ja) * | 1993-11-19 | 1995-06-02 | S R L:Kk | アレルゲン特異的IgE抗体の測定方法および抗原抗体複合体の測定方法 |
JP2005040784A (ja) * | 2003-07-10 | 2005-02-17 | Citizen Watch Co Ltd | マイクロ化学チップ温度調節装置 |
JP2006078364A (ja) * | 2004-09-10 | 2006-03-23 | Ntt Advanced Technology Corp | 表面プラズモン測定装置および測定方法 |
Non-Patent Citations (2)
Title |
---|
JPN7010002170; 庄子習一: 'マイクロ化学分析システム' 電子情報通信学会論文誌 C-1 Vol.J81-C-1, No.7, 19980731, pp.385-393 * |
JPN7012000175; Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, Jawa V, Koren E, Swanson SJ.: 'Immunogenicity Testing by Electrochemiluminescent Detection for Antibodies Directed against Therapeu' Clin Chem. Vol.51,No.10, 2005, Page.1983-1985 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013515260A (ja) * | 2009-12-22 | 2013-05-02 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 混合の改善された分析方法 |
WO2012161287A1 (ja) * | 2011-05-24 | 2012-11-29 | コニカミノルタアドバンストレイヤー株式会社 | 薄膜状素材の熱応答性測定方法および薄膜膜厚測定装置 |
JP2015531487A (ja) * | 2012-10-03 | 2015-11-02 | ユィロス・パテント・アクチボラグGyros Patent AB | 酸性条件でアナライトを測定するための方法およびキット |
US10036745B2 (en) | 2012-10-03 | 2018-07-31 | Gyros Patent Ab | Method and kit for analyte determination at acidic conditions |
Also Published As
Publication number | Publication date |
---|---|
WO2008033073A1 (en) | 2008-03-20 |
US20100167422A1 (en) | 2010-07-01 |
EP2062052A1 (en) | 2009-05-27 |
EP2062052A4 (en) | 2010-02-03 |
US8263415B2 (en) | 2012-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8263415B2 (en) | Method of determining analyte concentration | |
US20210215613A1 (en) | Concentration assay | |
EP1766398B1 (en) | Method for detecting molecular surface interactions | |
Yu et al. | Detection of low-molecular-weight domoic acid using surface plasmon resonance sensor | |
Englebienne et al. | Surface plasmon resonance: principles, methods and applications in biomedical sciences | |
Zhao et al. | Interfacial immobilization of monoclonal antibody and detection of human prostate-specific antigen | |
US7405054B1 (en) | Signal amplification method for surface plasmon resonance-based chemical detection | |
US8093005B2 (en) | Preparation and use of a reactive solid support surface | |
US20120264233A1 (en) | Method of analysis with improved mixing | |
Chung et al. | Additive assay of cancer marker CA 19-9 by SPR biosensor | |
CN101583872A (zh) | 测定待分析物浓度的方法 | |
Liu et al. | Sensitivity-enhancement of wavelength-modulation surface plasmon resonance biosensor for human complement factor 4 | |
EP1739427A1 (en) | Measurement method using biosensor | |
Zhou et al. | Polymeric microsphere enhanced surface plasmon resonance imaging immunosensor for occult blood monitoring | |
Chung et al. | Sequential analysis of multiple analytes using a surface plasmon resonance (SPR) biosensor | |
Liedberg et al. | Affinity biosensing based on surface plasmon resonance detection | |
Cusano et al. | Metasurface-assisted Lab-on-fiber optrode for highly sensitive detection of vitamin D | |
JP5205293B2 (ja) | 抗体固定基板、並びに該抗体固定基板の製造方法及び利用 | |
Ivarsson et al. | Surface plasmon resonance: development and use of BIACORE instruments for biomolecular interaction analysis | |
Nilvebrant | Kinetic analysis and epitope binning using surface plasmon resonance | |
Viguier et al. | Trends and perspectives in immunosensors | |
Zhao et al. | A novel optical immunosensing system based on measuring surface enhanced light scattering signals of solid supports | |
JP4751387B2 (ja) | 分子表面相互作用を検出する方法 | |
EP2798353B1 (en) | Method for detection of binding | |
US20030103901A1 (en) | ELISA kit for the determination of CYP2C19 metabolic phenotypes and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100827 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100827 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110912 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20110912 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110915 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120409 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120618 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130319 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130820 |